15 completed. 15 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 15 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow Vulvitis: new trials by email Literature Review of Vulvitis trials Research Report on Vulvitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Fluconazole, SCY-078 - Candida Vulvovaginitis | Phase 2 | Completed | Scynexis, Inc. | 186 | 2017-08-01 | 2021-08-12 |
| ProF-001_Phase IIa Candiplus, Clotrimazole - Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Completed | ProFem GmbH | 84 | 2017-04-04 | 2019-03-14 |
| Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Oral Encochleated Amphotericin B (CAMB), Fluconazole - Vulvovaginitis, Yeast Infection | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 137 | 2016-11-01 | 2018-11-02 |
| TOL-463 Phase 2 Study for Vaginitis TOL-463 - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 2 | Completed | Toltec Pharmaceuticals, LLC | 106 | 2016-07-15 | 2018-03-09 |
| RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%) - Candidiasis, Vulvovaginal, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 126 | 2016-06-08 | 2020-08-31 |
| Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis SCY-078, Fluconazole - Vulvovaginal Candidiasis | Phase 2 | Completed | Scynexis, Inc. | 96 | 2015-11-01 | 2019-07-12 |
| A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) VT-1161, Placebo - Recurrent Vulvovaginal Candidiasis | Phase 2 | Completed | Viamet | 254 | 2015-02-10 | 2019-10-15 |
| Probiotic Implementation as Help in Solving Vaginal Infections Lactobacillus rhamnosus BMX 54 - Vaginal Infection, ASC-US | Phase 2 | Completed | University of Roma La Sapienza | 117 | 2015-02-01 | 2017-12-13 |
| A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) VT-1161, Fluconazole - Candidiasis, Vulvovaginal | Phase 2 | Completed | Viamet | 55 | 2013-08-01 | 2018-08-01 |
| Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis NDV-3A, NDV-3, Placebo - Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Completed | NovaDigm Therapeutics, Inc. | 188 | 2013-07-01 | 2018-07-18 |
| MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis MGCD290 - Vulvovaginal Candidiasis | Phase 2 | Completed | MethylGene Inc. | 220 | 2011-12-01 | 2013-04-04 |
| Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), Placebo - Bacterial Vaginosis, Candidiasis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 234 | 2011-04-01 | 2014-10-06 |
| Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment arasertaconazole nitrate, placebo - Vulvovaginal Candidiasis | Phase 2 | Completed | Ferrer Internacional S.A. | 229 | 2010-06-01 | 2013-10-09 |
| Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis capsaicin, Placebo - Interstitial Cystitis, Vulvar Diseases | Phase 1 / Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 139 | 1995-06-01 | 2025-05-04 |
Candidiasis, Vulvovaginal (14) · Candidiasis (3) · Vaginitis (2) · Vaginosis, Bacterial (2) · Atypical Squamous Cells of the Cervix (1) · Cystitis, Interstitial (1) · Mycoses (1) · Papillomavirus Infections (1) · Rare Diseases (1) · Torulopsis (1) · Trichomonas Infections (1) · Urogenital Diseases (1) · Vaginal Diseases (1) · Vulvar Diseases (1) · Vulvar Vestibulitis (1)
Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Genital Diseases (15) · Genital Diseases, Female (15) · Bacterial Infections and Mycoses (14) · Infections (14) · Urogenital Diseases (14) · Vulvar Diseases (14) · Mycoses (13) · Vaginal Diseases (13) · Vulvovaginitis (13) · Vaginitis (12) · Candidiasis (11) · Bacterial Infections (2)
Fluconazole (5) · VT-1161 (2) · ibrexafungerp (2) · Capsaicin (1) · Clotrimazole (1) · Miconazole (1) · TOL-463 (1)
Scynexis, Inc. (2) · Viamet (2) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Ferrer Internacional S.A. (1) · Matinas BioPharma Nanotechnologies, Inc. (1) · MethylGene Inc. (1) · Min-Tze LIONG (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · NovaDigm Therapeutics, Inc. (1) · ProFem GmbH (1) · Toltec Pharmaceuticals, LLC (1) · University of Roma La Sapienza (1)
United States (10) · Austria (1) · Dominican Republic (1) · India (1) · Kenya (1) · Malaysia (1) · Spain (1)
David Angulo, MD (2) · Alena Jandourek, MD (1) · Douglas Kling (1) · Gregory Reid, MSc, MBA (1) · Herbert Kiss, Ao.Univ.Prof.Dr. (1) · Hugh Flood (1) · John P. Hennessey, Jr., Ph.D. (1) · Sumita Bhatia, MD (1)
PMID 36396498, PMID 29304768, PMID 29534874, PMID 29697768, PMID 30184181, PMID 32818963, PMID 34555149, PMID 40970688
2009 (1), R01DK049524 (1)